The Phenomics Australia In Vitro node, based at the Harry Perkins Institute of Medical Research, is a leading research infrastructure focused on advancing cancer treatments and medicines.
By fostering collaboration, it offers a comprehensive pipeline that includes a cancer tissue biobank, research data platforms, and a digital space for analysing and sharing integrated research and clinical data.
Equipped with cutting-edge technology, this facility utilises advanced preclinical models like cancer organoids to assess immunotherapy drugs with greater accuracy. These models are essential for evaluating new treatments and combination therapies. Working closely with surgeons, pathologists and oncologists across Perth hospitals, Biobank staff collect and characterise tumour samples. Through the Perkins Cancer Biobank, the Node generates patient-derived organoids for discovery research and preclinical evaluation of new and repurposed drugs.
Using omics technologies, the samples undergo molecular analysis, aiding preclinical evaluations and boosting clinical trial success. This data also drives biomarker development to monitor pharmacodynamics, predict drug response, improving personalised treatments for cancer patients.
Contact us to explore the expertise and services provided by the Phenomics Australia Perkins In Vitro Node.
